- 5RO1 ES012171-04 (PI, Awasthi); Protection of Oxidant Toxicity of GSTs; 12/15/03-11/30/08; annual direct costs, $200,000.
- 2RO1 EY004396-24 (PI, Awasthi); Detoxification of Xenobiotics in Ocular Tissues; 05/01/06-03/31/11; annual direct costs, $225,000.

- R01 AI067847 (PI, Barrett); Epidemiology and mosquito competence of West Nile virus; 6/1/06-5/31/11; annual direct costs, $250,000.
- T32 AI07526 (PI, Barrett); Emerging and Tropical Infectious Diseases; 09/01/03-08/31/08; annual direct costs, $134,000.

- RO1 HL65416 (PI, Boor); Glutatione S-Transferases: Oxidative Stress in Early Atherosclerosis; 04/01/02-03/31/08; annual direct costs, $200,000.
- R21 ES013038; 04/01/02-03/31/08; Fetal Basis of Dissecting aortic aneurysm; 04/01/04-03/31/07; annual direct costs, $100,000.

- RIA06625 Research into Ageing (Co-PI, Boulton); Neural plasticity in retinal ganglion cells; 10/05-10/08; annual direct costs, £70,000.
- EP/C013220/1 EPSRC: PLATFORM (Co-PI, Boulton); Bioresponsive polymer therapeutics; synthesis and characterisation of novel biomedicines; 07/05-07/10; annual direct costs, £418,422.
- G0500790 Medical Research Council (Co-PI, Boulton); The OPA1 gene and its involvement in cataractogenesis; 04/06-04/09; annual direct costs, £200,000.
- G0600053 Medical Research Council (Co-PI, Boulton); Raman spectroscopic evaluation of protein modification: a new, non-invasive diagnostic tool for age-related eye; 10/06-10/08; annual direct costs, £433,128.
- DHSS-RD-06-25 DHSS R&D (Co-PI, Boulton); Is Age-related Macular Degeneration Less Common in Light-protected Populations?; 10/06-10/09; annual direct costs, £341,192.
- 7-2005-875] JDRF (PI, Boulton); Novel mechanisms and therapies targeting dysfunctional endothelium, Project 1 “Endothelial precursors and diabetic retinopathy”; 01/07-12/09; annual direct costs (subcontract with University of Florida), $27,500.
- R01 EY007739-17 DHHS, National Eye Institute (PI, Boulton); Circulating progenitors determine angiogenic outcome in diabetic retinopathy; 02/07-12/12; annual direct costs (subcontract with University of Florida) $49,937.

- NO1 AI25488 (PI, Bourne); Drug Development for Opportunistic Infections-Cell and Animal Model Development for Hepatitis C; 09/23/02-09/22/09; annual direct costs, $452,350.

- NO1 AI30065 (PI, Stanberry); Small Animal Model Development and Proof of Concept Testing of Therapeutics and Vaccines in Small Animal Models of Burkholderia and Rickettsial Diseases; 09/30/03-09/29/10; annual direct costs, $1,431,452.

- RO1 HL968139 (PI, Calhoun); Mechanisms of Steroid Resistance in Severe asthma. 08/15/05-06/30/07; annual direct costs, $174,899.

- RO1 HL968139 (PI, Calhoun); Mechanisms of Steroid Resistance in Severe asthma. 08/15/05-06/30/07; annual direct costs, $174,899.

- RO1GM066170 (PI, Cheng); Epac/cAMP-GEF, a novel intracellular cAMP receptor; 05/01/03-04/30/08, annual direct costs, $172,569.
- 0755049Y (Am. Heart Association; PI, Cheng); Mechanisms of Exchange Protein Directly Activated by cAMP (EPAC)-Mediated Cardiomyocyte Hypertrophy; 07/01/07-06/30/09; annual direct costs, $59,091.

- RO1 AI041611 (PI, Chopra); Role of Virulence Factors in Aeromonas-mediated diseases; 03/15/03-02/28/08 (NCE); annual direct costs, $156,755.
- RO1 AI064389 (PI, Chopra); Identification of New Antigens for Plaque Vaccine; 02/01/05-01/31/10; annual direct costs, $250,000.

- 1RO1 DK 61470 (PI, Chung); Role of gastrin-releasing peptide in neuroblastomas; 01/03-12/07; annual direct costs, $225,000.

- RO1 DA06511 (PI, Cunningham); Neurobehavioral Pharmacology of Stimulants; 05/01/90-05/31/11; annual direct costs, $240,251.

- 1R01AI063513-01A2 (PI: Davey); Receptor trafficking in entry of murine leukemia viruses; 05/15/06- 04/30/2011; annual direct funds, $175,000.
- 1 U54 AI 057156-010004 (PI: Walker); Novel genetic tools for viral biodefense; 9/03-08/08; annual direct funds, $110,108.
- [Pending] 1 R21 GM076368-01 (PI: Davey); Nanoparticle Analysis of Enveloped Virus Entry Pathways; 12/01/2007-11/30/2010; annual direct costs, $125,000.

- 2 R01ES07800-11 (PI, Elferink); Ah Receptor Anatomy: Implications for Dioxin Toxicity; 12/1/2006 – 11/30/2011; annual direct costs, $225,000.
- 1 R01ES012018-01 (PI, Elferink); Ah Receptor Action and Apoptosis; 4/1/2005– 3/31/2010; $213,750.

- 1RO1 CA119075 (PI, Elferink); Cellular Responses to cMET Endocytosis; 08/30/06-07/31/11; annual direct costs, $142,000.

- U54 AI 057156 (PI, Walker); Rickettsial infection of humanized mice; 12/01/06-02/28/09; annual direct costs, $52,850.
- N01 AI30065 (L. Stanberry PI), Part C (Project Leader, Estes); Small Animal Model Development and Proof-of-Concept Testing of Therapeutics and Vaccines in Small Animal models of Burkholderia and Rickettsial Diseases; 10/01/06-08/01/09; annual direct costs, $3,248,556.
- U54 AI 057156 (D. Walker, PI); Discovery of subunit vaccine candidates against glanders. Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases; 05/01/05-04/30/08; annual direct costs, $171,022.
- U01 AI061441 (PI, Mason), subcontract Drexel University (PI, Estes); Iminosugars for Flaviviruses Infections of Bioterror; 04/01/05-03/31/08; annual direct costs, $64,109.
- N01 AI40097 (PI, Estes); In vitro and Animal Models for Emerging Infectious Diseases and BioDefense-Part E: Safety/Toxicology and Immunogenicity Testing for Vaccines; 9/29/04-09/29/09; annual direct costs, $3,996,767.
- SCA #58-1940-4-438 USDA-ARS (PI, Estes); Measuring Immune Responses to Vaccination with Foot-and-Mouth Disease Virus (FMDV) in Cattle; 07/01/04-06/30/09; $150,000
- CSREES-2005-35204-16039 USDA (Estes, D.M.); Prognostic indicators of cell-mediated immunity in cattle; 08/01/05-07/31/08; annual direct costs, $92,776.
- U19 AT003264 (subcontract with University of Missouri; Estes, PI); TICIPS: HIV/AIDS, secondary infections and immune modulation; 10/01/05-09/30/09; annual direct costs, $11,088.
- USDA Subcontract with TAMU (Estes, PI); Role of natural killer cells in FMDV in cattle-characterization and identification of modulation strategies; 10/01/05-09/30/07; annual direct costs, $226,758.
- CSREES-2005-35204-15996 USDA (PI, Shell); Characterization and functionality of bovine lung dendritic cells; 07/15/20-07/14/07; annual direct costs, $60,100.

- 2546-01, John Sealy Memorial Endowment Fund-Recruitment Grant (PI: Garg); The development of molecular tools for the functional characterization of GPIs in T. cruzi; 2/1/01-1/31/03; annual direct costs, $35,000.
- McLaughlin scholarship/NIH Pre-doctoral training grant [Garg (Mentor), M. Zacks (Graduate student trainee)]; Significance of GPI’s in T. cruzi; 8/1/01-7/31/04; annual direct costs, $30,000.

- Flight attendant Medical Research institute (PI, Garofalo); Protein Fingerprint of Airway Inflammation Induced by Viral Infection and Environmental Tobacco Smoke Exposure; 07/01/05-06/30/08; annual direct costs, $100,000.
- ImmunoBiosciences, Inc. (PI, Garofalo); Application of Immune Complex Vaccine (ICV) Technology Towards the Development of Human Respiratory Syncytial Virus (HRSV) Mucosal Vaccine; 06/01/07-05/31/09, annual direct costs, $100,000.
- NO1 AI30039 (PI, Couch); Viral Respiratory Pathogen Research Unit, subcontract (PI, Garofalo) “Role of Airway Epithelium in the Pathogenesis of RSV-Induced Lung Inflammatio; 09/01/03-08/31/10; annual direct costs, $169,350.
- NO1 HV28184 (PI, Kurosky; Co-PI, Garofalo); Proteomic Technologies to Study Airway Inflammation; 10/01/02-9/30/09; annual direct costs, $130,000.
- PO1 AI062885 (PI, Brasier); Signaling in Airway Inflammation, Project 1 (Project Leader, Garofalo); 07/01/05-03/31/10; annual direct costs, $134,159.
- RO1 AI069152 (PI, Rajarathnam); Role of Chemokine Monmer-Dimer Equilibrium in Innate Immunity and Inflammation; 05/01/06-04/30/11; annual direct costs, $225,000.

- R01 AI52428 (PI, Goldblum); Phylogenetic approach to plant allergy vaccines; 03/01/2004-04/30/2008; annual direct costs: $200,000.
- P30 ES006676 (PI: Halpert); Cellular Response Mechanisms to Environmental Challenge; 04/01/1995-03/31/2010; annual direct costs: $1,102,935.
- EPA (PI: Braun; Co-PI: Goldblum); Risk assessment of food allergenicity by a database approach; 10/01/2006-09/30/2009; annual direct costs: $125,000.
- Industry (Co-PI: Goldblum); ALK-Abello, Design reagent for development of a quantitative assay for group 1 allergens in extracts of Cupressaseae and Taxodiaceae pollens; 09/01/2006-08/31/2007; annual direct costs: $21,224.
- Biomedical Research Award (PI: Midoro); American Lung Association, Structure and function of allergens in asthma pathogenesis; 07/01/2006-6/30/2008; annual direct costs: $40,000.
- K08 AI55792 (PI: Midoro); NIH/NIAID, Structural biology of cedar pollen allergy; 04/04/2004-03/31/2008; annual direct costs: $474,248.
- [Pending] R21 (PI: Midoro); NIH/NIAID, Perinatal exposure to environmental estrogens and asthma pathogenesis, 12/01/2007- 11/30/2009; annual direct costs: $150,000.

- R01 DK038217 (PI, Good); Regulation of Thick Ascending Limb Acid-Base Transport; 07/01/1987-05/31/2008; annual direct costs, $182,940.

- ImmunoBiosciences, Inc. (PI, Garofalo; Co-PI, Guerrero-Plata); Application of Immune Complex Vaccine (ICV) Technology Towards the Development of Human Respiratory Syncytial Virus (HRSV) Mucosal Vaccine; 06/01/07-05/31/09, annual direct costs, $100,000.

- Sealy Foundation (PI, Hellmich); Studies of a Novel CCK-B/Gastrin Receptor Splice Variant; 05/15/07-05/15/08; annual direct costs, $50,000.
- 5R01 DK 48345 (PI, Townsend); Surgical Studies of GI Peptides - Mechanisms of Action; 08/01/94-07/31/08; annual direct costs, $270,577.
- PO1 DK35608 (PI, Townsend), Core C (Tissue Culture Core, Director, Hellmich), Core D (Peptide Receptor Core, Co-Director, Hellmich), Project 3 (Co-I, Hellmich); Studies in Gastrointestinal Endocrinology (Project 3, “Role of Mitogen-activated Protein Kinases in GI Peptide Hormone Receptor Signaling: Novel Mechanisms of Signal Integration”); 06/01/05-05/31/10; annual direct costs, $1,034,780.
- 5 R01 DK061470 (PI: Chung, Dai); Role of Gastrin-Releasing Peptide in Neuroblastoma; 01/01/03-12/31/07; annual direct costs, $175,770.
- 1RO1 DK058119-01A1 (PI, Hellmich); Studies of a Novel CCK-B/Gastrin Receptor Splice Variant; 07/01/01-05/31/07; annual direct costs (NCE), $186,495.

- P50 GM60338 (PI, Herndon): Burn Center Grant: assessment of Anabolic Agents/Exercise in Burn Children; Project 1, Administrative Core, Human Subjects Core: 03/01/00-07/10/10: annual direct costs, $429,674 (Project 1), $102,241 (Administrative Core), $187,450 (Human Subjects Core).
- T32 GM08256 (PI, Herndon); Postdoctoral Training in Trauma and Burns; 07/01/90-06/30/11; annual direct costs, $103,004.
- SHCG8660 (PI, Herndon); Assessment of the mechanisms of Improved Wound Healing and Protein Metabolism of Insulin in Severely Burned Patients; 01/01/92-12/31/08; annual direct costs, $235,904.

- R01 AI067847 (PI, Barrett); National Institutes of Health (PI, Barrett); West Nile Virus: Epidemiology and Mosquito Competence; 07/01/06-06/30/11; annual direct costs, $250,000.
- Sanofi-Pasteur (PI, Higgs); Characterize Seven Viruses of Two Colonies of Ae; 04/01/06-03-31/07; annual direct costs, $214,191.
- Cerus Inc. (PI, Higgs); Chikungunya Virus Inactivation Studies in Platelet Preparations; 2006-2007; annual direct costs, $75,000.
- Bill & Melinda Gates Foundation: Foundation for the National Institutes for Health (PI, Higgs); Developing Coupled Transgenic Ribozymes and Insecticide Resistance Approaches to Establishing Dengue Virus Refractoriness in Natural Aedes aegypti Populations; 2006-2007; annual direct costs, $56,350.

- UTMB recruitment and startup funds.

- DA 02073-27 (PI, Johnson); Neurochemical Pharmacology of Phencyclidine; 03/01/2004-02/29/2008; annual direct costs, $175,000).

- RO1 DK060105 (PI, Ko); Study of Growth Regulation in Surgical Diseases of Gut; 2001-2006; annual direct costs, $xxx,xxx.
- PO1 DK035608 (project PI, Ko); Studies in Gastrointestinal Endocrinology; 2005-2010; annual direct costs, $xxx,xxx.

- U19 AI040035 (PI, Lemon); Cooperative Hepatitis C Research Center, Project 1, Interferon signaling and cellular permissiveness for HCV; 07/01/06-06/30/10; annual direct costs, $183,195.
- NO1 AI2548801 (PI, Bourne); Drug Development for Opportunistic Infections-Cell and Animal Model Development for Hepatitis C; 09/23/02-09/22/09; annual direct costs, $164,525.
- Schering Plough Research Institute Contract @17336 (PI, Lemon); Development of Huh7-Derived Cell Lines Capable of Producing HCV Huh7 Cells; 05/10/07-05/09/09; annual direct costs, $82,412.

- RO1 AI069285 (PI, Li); Role of TLR3 Signaling in control of HCV; 03/15/07-02/28/12; annual direct costs, $175,000.

- R01 MH058448 (PI, Muma); Synergy Between SSRIs and Ovarian Hormones; 09/06 – 08/07; annual direct costs (subcontract), $4,000.
- 5 R01 NS034153 (PI, Battaglia); Serotonin reuptake inhibitors and 5-HT1A receptors; 01/07 – 12/07; annual direct costs (subcontract), $5,000.
- 1 R21 MH072938-01A1 (PI, Li); The Amygdaloid 5-HT2C Receptor in Anxiety-like Behavior; 07/05 – 06/08; annual direct costs, $100,000.

- RO1 DK071076 (PI, Liu); Crosstalk of GKLF/b-catenin in the intestine; 07/01/07-06/31/12; annual direct costs, $250,000.

- RO1 AI071145 (PI, McBride); Protective Glycopeptide Immunodeterminants of Erhlichia chafeensis; 05/01/06-04/30/10; annual direct costs, $250,000.

- 1RO1 AI29984-12A2 (PI: Makino); Molecular Studies of Coronavirus Replication; 02/1/02-01/31/08; annual direct costs, $225,000.
- [Pending] 1RO1 AI072439-01A2 (PI: Shinji Makino); Analysis of SARS coronavirus-host cell interactions; 4/01/2008-3/31/2013; annual direct costs, $200,000.

- R41 CA121794 (PI, Frederickson, C); Fluorescent Tools for the Study of Metallothionein; 07/01/06 – 06/30/07; annual direct costs, $180,000.
- R01 GM 065388 (PI, Maret); Regulation of Cellular Zinc Distribution; 09/01/03-08/31/06; annual direct costs, $125,000.
- [PENDING] R01 GM 065388 (PI, Maret); Regulation of Cellular Zinc Distribution; 09/30/07-11/30/11; annual direct costs, $225,000.
- [PENDING] R01 GM 069823 (PI, Maret); Metallothionein and Oxidative Stress; 12/01/05-11/30/10; annual direct costs, $323,541.
- [PENDING] R01 GM 078534 (PI, Maret); The Role of Zinc in the Control of Hepatic Oxidative Stress; 04/01/07-03/31/11; annual direct costs, $274,990.

- U54AI057156 (PI, project 6); Novel Genetic Tools for Viral Biodefense; 9/03-8/08; annual direct costs, $450,000.
- U54AI057156 (PI, project 8); Development of Novel Pseudoinfectious Flavivirus Vsccines; 03/06-02/08; annual direct costs, $185,000.

- RO3 DA023454 (PI, Moron-Concepcion); PSD Protein Expression in Extinction of Morphine-Dependent Conditioned Behavior; 0701/07-06/30/08; annual direct costs, $50,000.

- AMSL-RO-WA-SBIR, Dept. of the Army [PI (Nomadics), Wang; PI (UTMB), Nichols]; 3D Scaffold and Stem cell Based Bioengineered Skin for Treatment of Cutaneous Vessicant Injury; 04/12/05-04/11/10; annual direct costs, $70,000.
- BAA-01-42, Phase II, DARPA (PI, Nichols); Ex-vivo Replication of Immune Functions of Bone Marrow and Thymus on Three-dimensional Scaffolds; 11/01/04-10/31/07; annual direct costs, $973,032.
- Alliance for NANO-health, DOD (PI, Nichols); Nano-Therapeutics to Enhance Wound Healing; 02/07-03/08; annual direct costs, $199,938.

- R01 CA109136 (PI: O'Connor); Novel Mechanisms of Carcinoma Cell Migration; 03/09/06-12/31/10; annual direct costs, $172,353.
- R21 GM071928 (PI: O'Connor); Spatial Control of cAMP/PKA by Integrin Receptors; 09/30/04-08/31/07; annual direct costs, $150,000.
- P01 DK35608 (PI: Townsend): Studies in Gastrointestinal Endocrinology: 06/01/05-03/31/10: annual direct costs, Project 5, $101,087; Core E, $67,181.
- R01 NG00258 (PI: Falzon, Miriam); Intracrine Role of PTH-Related Protein in the Metastasis of Breast Cancer Cells to the Bone; 03/01/08-02/28/13; annual direct costs, $250,000.
- R01 CA118405 (PI: Sastry); Regulation and Function of PTP-PEST in Colon Carcinoma; 05/01076-02/29/12; annual direct costs, $190,000.

- NO1 AI25489 (PI, Tesh); Emerging Viral Disease Unit; 09/30/02-09/29/09; annual direct costs, $334,173.
- U54 AI057156 (PI, Walker); Region VI Center for Biodefense and Emerging Infections; (PI, Peters), Director of the BSL4 Core Facility; 9/04/03-02/29/08; annual direct costs, $431,078.
- U54 AI057156 (PI, Walker); Region VI Center for Biodefense and Emerging Infections; (PI, Peters), New Opportunities; 9/04/03-02/29/08; annual direct costs, $140,650.
- NOOO14-04-1-0660, Homeland Security (PI, Clarke); National Center for Foreign Animal and Zoonotic Disease Defense (subcontract); 08/01/04-07/31/07; annual direct costs, $134,780.
- 1UC1 AI062636-01 (PI, Peters); Rift Valley Fever Virus MP-12 Vaccine Completion; 09/15/04-12/31/07; annual direct costs, $1,743,875.
- NO1- AI-30039 (PI, Couch); Viral Respiratory Pathogens Research Unit (VRPRU-SARS); 07/01/04-06/30/07; Subcontract Viral Respiratory Pathogens, Mononuclear SARS supplement, VLP SARS supplement, annual direct costs, $379,495.

- 5R01 AI50086-04 (PI: Peterson); New Mechanisms in the Pathogenesis of Cholera; 04/01/02-04/30/07; annual direct costs, $200,000.
- DAMD170210699 (Army; PI: J. Peterson); Therapeutic Advances for Inhalational Anthrax; 09/01/02-9/30/07; annual direct costs, $254,321.
- U01 AI5385802 (PI: J. Peterson); Development of Therapeutic Inhibitors to Anthrax Toxins; 09/30/02-07/31/07; annual direct costs; $357,757.
- K-5U01 AI56559 (subcontract PI: Peterson); Advanced Anthrax Vaccine Made with ISS DNA Formulation; 07/15/03-12/31/07; annual direct costs, $103,710.
- Mission Pharmacol (PI: Peterson); The Antisecretory Potential of PGE2-L- Histidine; 06/03/02-06/30/08; annual direct costs, $294,070.
- N01-AI-30065 (PI: Peterson); Animal Models for Category A agents (B. anthracis) Part C1-Antibiotic evaluation; 09/30/03-09/30/08; annual direct costs, $209,527.
- N01-AI-30065 (PI: Peterson); Animal Models for Category A agents (B. anthracis) Part C10-Antitoxic drugs and monoclonals to anthrax PA; 03/31/04-03/31/09; annual direct costs, $197,943.
- N01-AI-30065 (PI: Peterson); Animal Models for Category A agents Part C13-Therapeutics against B. anthracis, Yersinia pestis, and Francisella Tularensis; 05/31/05-05/31/08; annual direct costs, $297,738.
- N01-AI-30065 (PI: Peterson); Development and Proof-of-Concept Testing of Therapeutics and Vaccines in Small Animal models of Burkholderia and Rickettsial Diseases; 09/30/06-09/29/07; annual direct costs, $3,248,556.

- PO1 (Project 3 PI, Pyles): Sexually-Transmitted Infections Center Grant, Project 3 “Microbiocides and Toll-like Receptors;” 2005-2010; annual direct costs, $171,642.
- NO1 AI25488 (PI, Bourne; Director phase II, Pyles); Drug development for Opportunistic Infections-Cell Culture Model Systems for Hepatitis C; 2002-2009; annual direct costs, $4,400,000.
- RO1 AI052372 (PI, Bourne), Immunization to Reduce Genital and Neonatal Herpes; 2003-2007; annual direct costs, $1,648,075.

- U54 AI057156 (WRCE, PI, Walker; PI this project, Roberts); Risks and Interventions for Pandemic Influenza; annual direct costs, $186,914.

- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation; 08/01/04-07/31/09; annual direct costs, $174.338.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 1 (PI, Hawkins) “Neuropeptide Mediation of Inflammation in Acute Lung Injury”; 08/01/04-07/31/09; annual direct costs, $174.338.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 2 (PI, Traber) “Role of NO and Vitamin E in Smoke Inhalation and Burn Injury”; 08/01/04-07/31/09; annual direct costs, $238,317.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 3 (PI, Schmalstieg) “Role of IL-8 in Inflammation Secondary to Smoke Inhalation and Burn Therapy”; 08/01/04-07/31/09; annual direct costs, $136.766.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 4 (PI, Zwischenberger) “Role Ventilator Damage Inflammation in Burn and Inhalation Injury”; 08/01/04-07/31/09; annual direct costs, $113.869.
- RO1 GM60688 (PI, Traber); The role of Selectins in Burns and Inhalation Injury; 07/01/05-06/30/10; annual direct costs, $250,000.
- SHCG8850 (Shriners of North America; PI, Schmalstieg); Neutrophil apoptosis in Smoke and Burn Injury; 01/01/04-12/31/07; annual direct costs, $107,000.
- SHCG8700 (Shriners of North America; PI, Zwischenberger); Paracorporeal Artificial Lung (PAL) for Lethal Smoke Burn Injury; 01/01/04-12/31/07; annual direct costs, $149,015.
- SHCG8530 (Shriners of North America; PI, Zwischenberger); A Prospective Randomized Outcomes Study of Three Gentle Ventilation Techniques (AVOO2R, HFPV, and LTV) in a Prospective, randomized, 10-day Outcomes Study Artificial Lung (PAL) for Lethal Smoke Burn Injury; 01/01/04-12/31/07; annual direct costs, $241,879.
- R42 HL071345 (PI, Zwischenberger); ambulatory Arteriovenous Carbon Dioxide Removal (A-AVCO2R); 09/01/04-06/30/07; annual direct costs, $95,535.
- SHCG8954 (PI, Traber); Multi-Center Project: Effects of Nitric Oxide in Burn and Smoke Inhalation Injury; 01/01/05-12/31/07; annual direct costs, $317,675.
- R44 HL064528 (PI, Nemser); Enhanced Long-Term Care of Severe Respiratory Failure; 01/01/05-12/31/07; annual direct costs, $138,000.
- R42 HL065030 (PI, Freidenreich); Modified Tetracycline Effects on Sepsis-Induced Mortality; 12/01/04-11/30/07; annual direct costs, $149,733.

- RO1 CA097959 (PI, Singh); Gastrins and Receptors in Colon Carcinogenesis; 07/01/03-06/30/08; annual direct costs, $200,000.
- RO1 CA114264 (PI, Singh); Growth Factors, Curcumin and Colon Carcinogenesis; 01/02/06-01/30/10; annual direct costs, $140,000.

- 1RO1 AI069142-01A1 (PI: Sun); Immune Mechanisms of HCV Persistence and Pathogenesis; 02/01/2007-01/31/20012; annual direct costs, $225.000.

- R21 NS953986 (PI, Taglialatela); Role of Calcineurin in Ab-Promoted Behavioral Deficits; 07/01/06-06/30/08; annual direct costs, $150,000.

- 1-05-RA-134 (American Diabetes Association; PI, Tilton); Chronic NF-κB Activation: Mechanisms, Inhibition, and Role in Diabetes; 1/2005 – 6/2007; annual direct costs, $100,000.
- 7-07-RA-169 (American Diabetes Association; PI, Tilton); Diabetes-induced noncanonical NF-κB activation in renal tubular epithelial cells; 7/2007 – 6/2010; annual direct costs, $100,000.

- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation; 08/01/04-07/31/09; annual direct costs, $174.338.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 1 (PI, Hawkins) “Neuropeptide Mediation of Inflammation in Acute Lung Injury”; 08/01/04-07/31/09; annual direct costs, $174.338.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 2 (PI, Traber) “Role of NO and Vitamin E in Smoke Inhalation and Burn Injury”; 08/01/04-07/31/09; annual direct costs, $238.317.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 3 (PI, Schmalstieg) “Role of IL-8 in Inflammation Secondary to Smoke Inhalation and Burn Therapy”; 08/01/04-07/31/09; annual direct costs, $136.766.
- PO1 GM066312 (PI, Traber); Pathophysiology of Lung Injury as a Result of Smoke Inhalation, Project 4 (PI, Zwischenberger) “Role Ventilator Damage Inflammation in Burn and Inhalation Injury”; 08/01/04-07/31/09; annual direct costs, $113.869.
- RO1 GM60688 (PI, Traber); The role of Selectins in Burns and Inhalation Injury; 07/01/05-06/30/10; annual direct costs, $250,000.
- SHCG8850 (Shriners of North America; PI, Schmalstieg); Neutrophil apoptosis in Smoke and Burn Injury; 01/01/04-12/31/07; annual direct costs, $107,000.
- SHCG8954 (PI, Traber); Multi-Center Project: Effects of Nitric Oxide in Burn and Smoke Inhalation Injury; 01/01/05-12/31/07; annual direct costs, $317,675.

- TaiGen Biotechnology 491450 (PI, Tseng); Evaluation of anti-SARS compounds in animal models; 09/01/05-06/30/07; annual direct costs, $160,000.
- NO1-AI-30039 (PI, Couch); Subcontract- Viral Respiratory Pathogens Research Unit (VRPRU-SARS); 07/01/05-06/30/08; annual direct costs, $110,000.
- R21 AI-063118-01 (PI, Chan); SARS: A transgenic mouse model for pathogenesis, treatment, and vaccine studies; 09/01/05-08/31/07; annual direct costs, $125,000.
- NO1 AI15435 (PI, Chan, Subcontract from the University of Utah); Trangenic Mouse Models for SARS; 10/01/06-09/30/07; annual direct costs, $150,000.
- U54 AI057156 (WRCE, PI, Walker); Antiviral Agents as Therapy for SARS (Tseng); 09/01/06-08/31/08; annual direct costs, $100,000.

- RO1 ES15292 (PI, Watson); Nongenomic Signaling Mechanisms of Environmental Estrogens; 12/2006-11/2010; annual direct costs, $175,000.
- Sealy Memorial Endowment Fund (PI, Watson); Environmental Estrogens Acting Through a Membrane Receptor; 07/2006 – 06/2007; annual direct costs, $20,000.
- American Institute for Cancer Research (PI, Watson); Phytoestrogen-induced Nongenomic Signaling Cascades and their Functional Consequences in Pituitary Cancer; 01/2007-12/2009; annual direct costs, $82,500.
- 5 P30 ES006676-13 (PI, Watson); Environmental Estrogen Signaling in Disruptions of Behavioral, Reproductive, and Immune Responses; 05/2007-04/2008; annual direct costs, $25,000.

- R01 DK038217 (PI, Good); Regulation of Thick Ascending Limb Acid-Base Transport; 07/01/1987-05/31/2008; annual direct costs, $182,940.
- American Heart Association # 0565159Y (PI: Watts); Regulation of Renal Transport by Neurotrophins; 07/01/05 – 12/31/07; annual direct costs: $56,363.

- RO1 NS046025 (PI, Wu); Stem Cell Therapy for Motorneuron Degeneration; 09/30/03-06/30/07; annual direct costs, $208,000.

- 1R01CA094160-01 (PI, Xie); Molecular basis of hedgehog signaling in carcinogenesis; 2/1/02- 12/31/08 (NCE); annual direct costs, $182,450.
- PC030429; Department of Defense (PI, Xie); The role of the sonic hedgehog pathway in prostate cancer progression; 03/31/03-03/30/09 (NCE); annual direct costs, $69,587.

- R21 AI063451 (PI, Yi); Functions of NS3 in HCV RNA; 06/15/05-05/31/08 (NCE); annual direct costs, $141,475.

- UO1 AI71283 (co-PI, Yu); Vaccine for Epidemic Typhus; 09/30/06-09/29/11; annual direct costs, $230,437.